The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis

Not Your Average Case: Difficult-to-Treat Rheumatoid Arthritis

July 15, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Using this definition of difficult-to-treat RA, 5–20% of all patients with RA may fit into this category.2

You Might Also Like
  • Just in Case: Understanding Rheumatoid Arthritis Through Patient Cases
  • Janus Kinase Inhibitors Promising for Difficult-to-Treat RA
  • Treat Rheumatoid Arthritis to Target
Explore This Issue
September 2022
Also By This Author
  • The History of The Rheumatologist

Contributing Factors

Dr. van Laar discussed work that he and colleagues undertook to better understand the contributing factors and burden of disease seen in patients with difficultto-treat RA. In this prospective study, 52 patients with RA were classified as having difficult-to-treat disease and compared with 100 patients with RA who did not meet this definition.3 The authors identified lower socioeconomic status at the onset of RA as an independent risk factor for the development of difficult-to-treat disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Other factors that were independently associated with difficult-to-treat disease include limited drug options as a result of adverse events from therapy, mismatch between doctor and patient in the wish to intensify treatment, fibromyalgia and poorer coping skills. A higher prevalence of alcohol use, anxiety and depression was seen in patients with difficult-to-treat disease, compared with controls.

In evaluating the financial aspects of care, patients with difficult-to-treat RA generated about double the healthcare costs of patients without difficult-to-treat disease. The main driver of costs is not just medications, but also the time that family members, friends and relatives invest in caring for these patients. This leads to lost work productivity and collateral costs to these individuals and to society.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In evaluating the financial aspects of care, patients with difficult-to-treat RA generated about double the healthcare costs of those patients without difficult-to-treat disease.

Workflow

A workflow can be used in approaching patients with difficult-to-treat RA. If a patient with RA is showing persistent signs and symptoms of disease activity despite treatment, Dr. van Laar noted the clinician’s first step should be to see if the patient meets the EULAR definition of difficult-to-treat disease. The rheumatologist should then assess for comorbidities that can mimic the signs and symptoms of active disease or may interfere with arthritis assessment.

The rheumatologist should also evaluate whether arthritis activity is present, and in some cases where such an assessment is equivocal, use of ultrasound may be indicated. It is also important, in a professional and nonjudgmental way, to speak with the patient and see if medication nonadherence is at play. Once all of these issues have been evaluated and addressed, then changes to pharmacologic treatment can be made while simultaneously increasing focus on nonpharmacological treatments, which include patient education, increased physical exercise and self-management strategies that can help with coping with disease.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: difficult-to-treat RA, EULAR, EULAR 2022, patient care, RA Resource Center, Rheumatoid Arthritis (RA)Issue: September 2022

You Might Also Like:
  • Just in Case: Understanding Rheumatoid Arthritis Through Patient Cases
  • Janus Kinase Inhibitors Promising for Difficult-to-Treat RA
  • Treat Rheumatoid Arthritis to Target
  • Experts Discuss Unique Challenges Posed by Difficult-to-Treat RA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)